BEAUFORT
LIVE

Serial Number

97753728

Owner

BEAUFORT, LLC

Attorney

Robert J. Kenney

First Use Date

Dec 5, 2022

Filing Date

Jan 13, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BEAUFORT Trademark

Serial Number: 97753728 • Registration: 7509253

BEAUFORT is a trademark filed by BEAUFORT, LLC on January 13, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

BEAUFORT, LLC (4 trademarks)

999 Waterside Drive, Suite 1010
NORFOLK, VA 23510

Entity Type: 16

Trademark Details

Filing Date

January 13, 2023

Registration Date

September 17, 2024

First Use Anywhere

December 5, 2022

First Use in Commerce

December 5, 2022

Published for Opposition

November 21, 2023

Goods & Services

Consulting services in the field of manufacturing compliance and validation, namely, providing technical advice related to the manufacture of pharmaceuticals

Regulatory submission management, namely, assisting others in preparing Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; database management; organizing and administering a network of research sites, namely, business consultation and management in the field of clinical trials, specifically, providing governmental registration assistance in the nature of regulatory submission management on behalf of research sites that conduct gene therapy and vaccine research to assist them with clinical research and clinical trials; providing institutional biosafety committee services, namely, providing independent review and oversight of clinical trials involving genetically engineered gene therapy and vaccine research for business purposes

Legal research, namely, regulatory research in the pharmaceutical industry, biotechnology industry and the medical and diagnostics industry; consultation in the field of regulatory compliance to ensure validity and accuracy of regulatory submissions to the FDA by life sciences companies; conducting regulatory and compliance audits for others, namely, reviewing standards and practices to assure compliance with laws and regulations in the fields of pharmaceutical, veterinary, pharmacogenomic, biotechnical and medical products and devices; providing information relating to legal affairs, namely, providing regulatory information relating to the development and validation of drugs, devices and biologics; regulatory compliance consulting as it applies to clinical trials, namely, monitoring by clinical research administrators for compliance with regulations governing clinical trials; legal document preparation services, namely, preparation of Investigational New Drug applications (INDs) and New Drug Applications (NDAs) for submission to the FDA; consulting services in the field of regulatory affairs and manufacturing compliance and validation, namely, regulatory compliance consulting as it applies to prescription drug sampling; consulting services in the field of clinical benchmarking and performance improvement, namely, providing independent review of clinical trials involving human subjects in the nature of reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research; providing regulatory compliance consultation services in the nature of advice concerning due diligence, strategic development, and regulatory policy in the field of clinical trials involving human subjects; providing information relating to regulatory compliance for independent review of clinical trials involving human subjects; providing institutional biosafety committee services, namely, independent review and oversight of clinical trials involving genetically engineered gene therapy and vaccine research, specifically, reviewing research protocols and related information to ensure protection of the rights and welfare of human subjects of research; assessing the readiness of research sites to conduct gene therapy and vaccine research, namely, reviewing standards and practices to assure compliance with laws and regulations in the field of clinical trials involving human subjects; regulatory compliance consultation services in the nature of health inspection readiness and remediation in the field of clinical, medical, and biological research studies; consultation services in the field of pharmacovigilance strategies to ensure regulatory compliance and patient safety in the field of clinical trials involving human subjects; regulatory compliance consultation services in the field of informed consent protocols for clinical trial participants; consultation services in the field of research compliance, namely, regulatory compliance consultation services in the field of clinical trials involving human subjects

Contract research organization (CRO) services, namely, monitoring of clinical trials for investigational drugs of biotech and pharmaceutical companies, clinical trial project management and quality assurance, medical writing of investigational drug protocols, and medical research in the nature of biostatistical analysis; consulting services in the field of conducting clinical trials, drug development, manufacturing environmental compliance and validation, advanced technology in the pharmaceutical field, and medical research in the nature of clinical benchmarking used to improve the performance of professionals in the fields of international health, the pharmaceutical industry, the biotechnology industry and the medical device and diagnostics industries; providing quality assurance services in the field of regulatory submissions to the FDA by life sciences companies to ensure validity and accuracy; product development for others, namely, providing implementation services relating to the development and validation of drugs, devices and biologics; providing institutional biosafety committee services, namely, review and oversight of clinical trials involving genetically engineered gene therapy and vaccine research, specifically, evaluating research sites involved in gene therapy and vaccine research clinical trials to determine whether the organizations conform to an established accreditation standard; assessing the readiness of research sites to conduct gene therapy and vaccine research, namely, testing, analysis, and evaluation of gene therapy and vaccine research service providers to determine conformity with established accreditation standards; consultation services in the nature of quality management, namely, quality evaluation and analysis, quality assurance, and quality control in the field of clinical, medical, and biological research studies; consultation services in the field of drug and medical device development; consultation services in the field of conducting clinical trials for others; consultation services in the field of scientific research compliance, namely, analysis and evaluation of scientific research of others in the field of clinical trials involving human subjects to assure compliance with industry standards; consultation services in the field of scientific research administration and operations in the field of clinical trials involving human subjects; consultation services in the field of product research and development and scientific research and development

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 17, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 17, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 15, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 15, 2024 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 4, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 4, 2024 AITU
USE AMENDMENT FILED
Jun 17, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 17, 2024 EISU
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 14, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 14, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 14, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 14, 2024 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 16, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Nov 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 18, 2023 CNSA
ASSIGNED TO EXAMINER
Oct 10, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 4, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 3, 2023 NWOS
NEW APPLICATION ENTERED
Jan 17, 2023 NWAP